HER2 mRNA Expression Profile and Its Correlation with ICC and FISH in FNAC Samples from Breast Cancer Patients
Divya Verma1,2*, Nisha Raj1, Dharam Veer Singh1, Manjari Baluni1, Mishra, R. N.2, Mukesh Verma2 & Ram Nawal Rao1
1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
2National Jewish Health, 1400 Jackson St. Denver, CO, USA-80206
Dr. Divya Verma, Department of Medicine, National Jewish Health, 1400 Jackson St. Denver, CO, USA-80206.
Keywords: Breast carcinoma, Her2/neu; Cell Block (CB); Immunocytochemistry (ICC); Fluorescence in Situ Hybridization (FISH); Fine Needle Aspiration (FNA); Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)
Context: Around 20-30% of breast carcinoma patients have HER2 overexpression, and they usually have a poor prognosis. With the advent of specific molecule targeting therapies, it is very important to determine overexpression or hyperactivity of the target in focus. Considering to these facts, diagnostic accuracy is very important to project the response of tentative candidate to Trastuzumab therapy because it specifically targets HER2. Although, all known tools for diagnostic purposes are more or less satisfactory but none of them have excellent accuracy and some, like tissue biopsy, are very invasive in nature. Fine-needle aspiration (FNA) is a reliable, quicker, and less invasive technique, widely used for diagnosis of invasive breast carcinoma. Immunohistochemistry (IHC), combined with different methods for in situ hybridization, is currently used for routine assessment of HER2 levels in tissue specimens.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).